Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have completed Study AMAN (NCT03518086), with at least 1 study drug administration and without early termination of study drug.
Are willing and able to complete the scheduled study assessments, including endoscopy and daily diary entry.
If female, must meet the contraception requirements.
You may not be if
Participants diagnosed with Crohn's disease or inflammatory bowel disease-unclassified (indeterminate colitis) during the induction study AMAN (NCT03518086).
Participants with a bowel resection or other surgery for the treatment of UC during the previous induction study AMAN (NCT03518086), or are likely to require surgery for the treatment of UC during study AMBG.
Participants with evidence of colonic dysplasia or have been diagnosed with cancer of the gastrointestinal tract during study AMAN (NCT03518086).
Participants diagnosed with clinically important infection including, but not limited to, hepatitis B, hepatitis C, HIV/AIDS, and active tuberculosis (TB) during the induction study AMAN (NCT03518086).
Participants who initiate a new prohibited medication during the induction study AMAN (NCT03518086).
Participants with certain laboratory abnormalities prior to start of AMBG that would require permanent discontinuation from study drug.
Clareo Health | A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis
